Abiraterone Acetate (ZYTIGA)
Showing 1 - 25 of 1,212
Abiraterone Acetate in Indian Metastatic, Castration Resistant
Withdrawn
- Prostate Cancer
- Abiraterone Acetate
-
Bangalore, India
- +2 more
Aug 15, 2022
Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (Abiraterone Acetate, Prednisone,
Active, not recruiting
- Prostatic Neoplasms
- Metastatic Castration-Resistant Prostate Cancer
- Abiraterone Acetate
- +2 more
-
Los Angeles, California
- +6 more
Jan 18, 2023
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Tumors Trial (MK-5684, Dexamethasone, Fludrocortisone
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Prostatic Neoplasms
- MK-5684
- +6 more
- (no location specified)
Nov 21, 2023
Medicines Called Enzalutamide and Abiraterone in People With
Not yet recruiting
- Prostatic Neoplasms, Castration-Resistant
- Enzalutamide
- Abiraterone acetate
-
New York, New YorkPfizer Inc
Jul 21, 2023
Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial in Shanghai (Abiraterone Acetate Tablets (I), ZYTIGA®)
Completed
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Abiraterone Acetate Tablets (I)
- ZYTIGA®
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Feb 16, 2022
Prostate Cancer Trial in Tampa (Abiraterone Acetate)
Active, not recruiting
- Prostate Cancer
- Abiraterone Acetate
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jan 3, 2023
Congenital Adrenal Hyperplasia Trial in United States (Abiraterone acetate, Placebo, Hydrocortisone)
Withdrawn
- Congenital Adrenal Hyperplasia
- Abiraterone acetate
- +3 more
-
Los Angeles, California
- +3 more
Jan 30, 2023
Prostate Cancer Metastatic, Prostate Cancer Trial in Houston (Abiraterone Acetate, Prednisone)
Recruiting
- Prostate Cancer Metastatic
- Prostate Cancer
- Abiraterone Acetate
- Prednisone
-
Houston, Texas
- +2 more
Oct 7, 2022
Metastatic Castration-resistant Prostate Cancer Trial (Abiraterone Acetate)
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- Abiraterone Acetate
- (no location specified)
Apr 19, 2022
Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer Trial in Baltimore, Boston, Seattle (Enzalutamide,
Completed
- Prostate Adenocarcinoma
- +2 more
- Enzalutamide
- +3 more
-
Baltimore, Maryland
- +3 more
Mar 30, 2022
Metastatic Castrate-Resistant Prostate Cancer Treated With
Completed
- Prostate Cancer
- Enzalutamide
- +2 more
-
Durham, North CarolinaDuke University Medical Center
Dec 22, 2020
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma Trial in Houston (Abiraterone Acetate, Bicalutamide, Degarelix)
Active, not recruiting
- Prostate Adenocarcinoma
- Recurrent Prostate Carcinoma
- Abiraterone Acetate
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 Trial in Duarte
Recruiting
- Castration-Sensitive Prostate Carcinoma
- +4 more
- Abiraterone Acetate
- +7 more
-
Duarte, CaliforniaCity of Hope Medical Center
Oct 7, 2022
Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Tumor in the Bone, Metastatic Prostate Carcinoma Trial in Seattle
Active, not recruiting
- Castration-Sensitive Prostate Carcinoma
- +7 more
- Antiandrogen Therapy
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 8, 2022
Prostatic Tumors, Castration-Resistant Trial in Leiden (Patient-specific adaptive therapy, Abiraterone acetate, Enzalutamide)
Recruiting
- Prostatic Neoplasms, Castration-Resistant
- Patient-specific adaptive therapy
- +2 more
-
Camperdown, New South Wales, Australia
- +6 more
Jan 11, 2023
Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer Trial in Sacramento (Abiraterone Acetate,
Active, not recruiting
- Metastatic Prostate Carcinoma
- +2 more
- Abiraterone Acetate
- +2 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Feb 23, 2022
Congenital Adrenal Hyperplasia Trial in United States (Abiraterone acetate)
Active, not recruiting
- Congenital Adrenal Hyperplasia
- Abiraterone acetate
-
Los Angeles, California
- +3 more
Feb 22, 2022
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage IV Prostate
Suspended
- Castration-Resistant Prostate Carcinoma
- +4 more
- Abiraterone Acetate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Apr 27, 2022
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8 Trial in Houston (drug,
Completed
- Prostate Adenocarcinoma
- +4 more
- Abiraterone Acetate
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jul 14, 2022
Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone Trial in Houston (Abiraterone
Active, not recruiting
- Metastatic Prostate Carcinoma
- +5 more
- Abiraterone Acetate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 26, 2022
Metastatic Castration-resistant Prostate Cancer Trial in China (olaparib, enzalutamide, abiraterone acetate)
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- olaparib
- +3 more
-
Chengdu, China
- +7 more
Aug 5, 2022
Prostate Cancer Trial in Durham, Houston (Abiraterone acetate, Androgen deprivation, Radiation Therapy)
Active, not recruiting
- Prostate Cancer
- Abiraterone acetate
- +3 more
-
Durham, North Carolina
- +2 more
Oct 27, 2021
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer Trial in Whittier, Lake Mary (Afatinib Oral Tablet,
Recruiting
- NSCLC Harboring NRG1 Fusion
- Metastatic Castration-resistant Prostate Cancer
- Afatinib Oral Tablet
- +3 more
-
Whittier, California
- +1 more
Dec 20, 2022